How long should first-line chemotherapy continue?

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Bertelsen, K ^c   Grenman, S ^a   Rustin, G J S ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Advanced ovarian cancer; Chemotherapy; Duration; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0032914703     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31479-4     Document Type: Conference Paper

References (14)

1. Bertelsen K, Jakobsen A, Strøyer J et al. A randomised study of cyclophosphamide + cisplatin with and without doxorubicin in advanced ovarian cancer. Gynecol Oncol 1987; 28: 161-9.
2. Tropé C, Andersson H, Bjorkholm E et al. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer. Acta Oncol 1996; 35 (Suppl 8): 109-18.
3. National Institute of Health Issues Consensus development conference statement ovarian cancer: Screening treatment and follow-up. Gynecol Oncol 1994; 55: 4-14.
4. Allen DS, Boah J, Belpomme D et al. Advanced epithelial ovarian cancer. 1993 consensus statements. Ann Oncol 1993; 4: 83-8.
5. Jacob JH, Gershenson DM, Morin M et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991; 42: 146-50.
6. Bruzzone M, Repetta L, Chiara S et al. Chemotherapy versus radiotherapy in the management of ovarian cancer with pathological complete response or minimal residual disease at second-look. Gynecol Oncol; 1990; 38: 392-5.
7. Bolis G, Favalli G, Danese S et al. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol; 1997; 15 (5): 1938-44.
8. Bertelsen K, Jakobsen A, Stroyer J et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Cancer Study Group Trial (DACOVA). Gynecol Oncol 1993; 49: 30-6.
9. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol; 1992; 45: 284-9.
10. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327-33.
11. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of doseintensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol; 1995 Jul; 13 (7): 1589-99.
12. Van der Burg ME, Van Lent IV, Buyse M et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med; 1995; 332: 629-34.
13. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE: A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 1993; 11: 440-8.
14. Sorbe B, Tropé C, Nordal R et al. Chemotherapy versus radiotherapy as consolidation treatment of ovarian carcinoma stage III at surgical complete remission from induction chemotherapy. Proc Am Soc Clin Oncol; 1996, 15: 287.